CMIT/MIT (2.0-2.5% in water)

CMIT/MIT (0.1875 mg/kg/day; transdermal administration; 5 days per week for 3 weeks) (2.0-2.5% in water) induces atopic dermatitis (AD)-like skin inflammation and Th2-related immune dysfunction in normal BALB/c mice; it promotes Th2/Th17-associated immune dysregulation, including a significant increase in serum total IgE levels and upregulated expression of IL-4/IL-17A in the skin^[2].
CMIT/MIT (1.5-15 a.i. mg/kg bw/day; oral administration; daily dosing from gestational day 5 to 15) (2.0-2.5% in water) causes dose-dependent maternal death in pregnant rats, but shows no teratogenicity or reproductive toxicity^[3].
CMIT/MIT (1.5-13.3 a.i. mg/kg bw/day; administered orally; daily dosing on gestational days 6-18) (2.0-2.5% in water) causes severe dose-dependent maternal mortality and fetal loss in pregnant rabbits^[3].
CMIT/MIT (2.0-2.5% in water) administered orally to dogs at doses ≥3.5 a.i. mg/kg bw/day over a two-week period triggers mild systemic adverse responses such as lowered food intake as well as changes in hematological and serum biochemical indicators^[3].
CMIT/MIT (2.0-2.5% in water) causes dose-dependent gastric irritation in rats at doses of 100 and 300 a.i. ppm, but shows no carcinogenicity or systemic toxicity following 2 years of oral administration^[3].
CMIT/MIT (2.0-2.5% in water) is a potent skin sensitizer in mice, with an EC₃ range of 0.75-2.1 a.i. μg/cm² in the local lymph node assay; dermal administration at a dose of 400 a.i. ppm for 30 months causes skin hyperplasia and inflammation in mice but no carcinogenicity; dermal administration at a dose of ≥ 0.56 a.i. mg/kg bw/day for 3 weeks induces moderate skin irritation in rabbits without associated systemic toxicity^[3].